A

AtriCure

Sells ablation devices for atrial fibrillation

Training & Education Manager - China

Full-TimeUpdated on 10/14/2026
No salary listed
Senior
Bachelor's, Master's
Beijing, China+1 moreMore locations: Shanghai, China
In Person
Customer Experience & SupportCustomer Education & Training

About the job

Requirements
  • A bachelor's degree is required.
  • A minimum of 5–8 years of experience in medical device, healthcare, pharmaceutical, or professional education functions is required.
  • Experience managing physician education programs and medical training activities is required.
  • Strong project management and stakeholder management skills are required.
  • Presentation, communication, and facilitation capabilities are required.
  • Ability to work effectively with key opinion leaders and healthcare professionals is required.
  • Willingness to travel approximately 30–50% is required.
Responsibilities
  • Develop and execute annual China training and education strategies aligned with commercial and therapy development objectives.
  • Deliver structured onboarding, competency development, and continuous learning programs for internal employees.
  • Design, implement, and evaluate physician education initiatives that support adoption of AtriCure therapies.
  • Establish scalable digital learning solutions to increase educational reach and learning effectiveness.
  • Collaborate with local and regional stakeholders to ensure educational activities are consistent, compliant, and high quality.
  • Measure program effectiveness using defined key performance indicators and continuously improve educational outcomes.
  • Develop annual China training and education plans and training calendars aligned with business priorities.
  • Identify training gaps and competency needs across sales, clinical, and customer segments.
  • Establish measurable objectives and key performance indicators for education programs.
  • Support new product launches and therapy expansion initiatives with targeted education plans.
  • Lead onboarding and certification programs for new hires.
  • Conduct refresher training for commercial and clinical teams.
  • Collaborate with Global and APAC training and education teams to localize training content.
  • Support development of field coaching and competency assessment programs.
  • Maintain learning records and training compliance requirements.
  • Plan and execute physician education activities, including didactic programs, hands-on workshops, dry-lab simulation training, proctorship programs, and training village activities.
  • Support education programs for cardiac surgeons, electrophysiologists, cardiologists, operating room nurses, and allied healthcare professionals.
  • Identify and support development of key training centers across China.
  • Collaborate with center-of-excellence faculty to establish standardized training pathways.
  • Coordinate site visits, case observation, and proctorship programs.
  • Ensure training programs align with therapy adoption objectives.
  • Identify potential faculty candidates and future speakers.
  • Support faculty onboarding and capability development.
  • Maintain faculty engagement plans and training records.
  • Collaborate with Commercial and Marketing teams on faculty strategy.
  • Develop and manage an annual webinar series covering clinical evidence updates, therapy adoption best practices, new technologies and product innovations, case-based learning, and guideline interpretation and implementation.
  • Coordinate webinar speakers, content development, promotion, execution, and post-event analytics.
  • Lead implementation and maintenance of digital learning tools for physicians and internal employees.
  • Collaborate with Global Professional Education and APAC Marketing to develop e-learning modules, on-demand training content, video libraries, and interactive clinical education resources.
  • Drive learner engagement and completion rates through innovative learning approaches.
  • Introduce educational initiatives that increase learning effectiveness and engagement.
  • Develop mobile-friendly learning resources.
  • Explore AI-enabled learning tools and digital education solutions where appropriate.
  • Support creation of localized China-specific learning content.
  • Manage Journal Club initiatives.
  • Develop quarterly knowledge assessment programs.
  • Create Clinical Nuggets and educational newsletters.
  • Maintain repositories of educational resources and reference materials.
  • Manage deployment and utilization of CADet platforms within China.
  • Maintain training inventory and simulation equipment.
  • Coordinate repairs, upgrades, and replacement of training assets.
  • Support logistics for workshops, conferences, and training villages.
  • Track utilization metrics and provide periodic reporting.
  • Lead planning and execution of educational events from initiation through completion.
  • Ensure consistent branding and participant experience across educational programs.
  • Develop and maintain standardized templates and execution checklists.
  • Implement participant feedback and assessment processes.
  • Analyze educational outcomes and program effectiveness.
  • Use data to continuously improve future activities.
  • Develop training dashboards and performance reports.
  • Track program attendance, learning completion, faculty participation, therapy adoption impact, and customer engagement indicators.
  • Provide regular updates to China and APAC leadership teams.
  • Partner with Sales, Therapy Development, Marketing, and the APAC training and education team.
  • Ensure educational activities comply with company policies and local regulations.
  • Support strategic projects and special initiatives as assigned.
Desired Qualifications
  • A master's degree is preferred.
  • Experience with digital learning platforms and webinar management is preferred.
  • Experience in cardiac surgery, electrophysiology, structural heart, or related cardiovascular therapies.
  • Experience establishing centers of excellence and faculty development programs.
  • Certification or experience in adult learning methodologies.
  • Experience with learning management systems and digital education platforms.
  • Demonstrated success in building physician education strategies that support therapy adoption.

About the company

AtriCure designs and sells medical devices to treat atrial fibrillation and related heart conditions. Its products include ablation systems, left atrial appendage management devices, and cryoablation tools used in open-heart and minimally invasive surgeries; these devices deliver energy to heart tissue to create precise lesions and manage blood flow. The company differentiates itself with an integrated AF-focused portfolio, combined with hands-on training and support for clinicians to ensure proper use in various surgical workflows. Its goal is to improve patient outcomes by providing reliable, easy-to-use devices and comprehensive clinician education.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Mason, Ohio

Founded

1994

Get referred to AtriCure

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $153.6 million, and management raised full-year guidance.
  • BoxX-NoAF enrollment surpassed 500 patients in July 2026, ahead of schedule.
  • cryoXT launched in 2025 and should contribute more meaningfully in late 2026.

What critics are saying

  • MIS ablation faces pulsed-field ablation cannibalization; Q1 2026 revenue there fell 25%.
  • Gross margin dips below 77% in Q3 2026 as the new plant ramps.
  • If BoxX-NoAF or LeAAPS miss, AtriCure loses its 2030 $1 billion thesis.

What makes AtriCure unique

  • AtriCure owns a surgical AFib niche spanning ablation, appendage management, and cryoanalgesia.
  • cryoSPHERE MAX and EnCompass drove Q2 2026 growth, highlighting surgeon adoption.
  • BoxX-NoAF and LeAAPS create label-expansion optionality unavailable to catheter ablation rivals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Wellness Program
  • 401(k) Company Match
  • Parental Leave
  • Pet Insurance
  • Employee Stock Purchase Plan
  • Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Sep 13th, 2026
AtriCure CTO sells $200K in shares, retains $7.9M stake

AtriCure's Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on 8 September 2026 at $55 per share, according to an SEC Form 4 filing. The transaction was executed under a Rule 10b5-1 trading plan established in February 2026. Privitera retains approximately 147,000 shares in the medical device company, valued at $7.9 million based on the 8 September closing price of $53.73. The stock has risen 49% over the preceding 12 months. AtriCure, which makes specialised devices for cardiac tissue treatment, reported trailing twelve-month revenue of $569.6 million and net income of $10.6 million. The company has a market capitalisation of $2.7 billion.

Yahoo Finance
Aug 12th, 2026
AtriCure targets $1B revenue by 2030 as pain management volumes jump 25%

AtriCure is targeting $1 billion in revenue by 2030, up from current guidance of $602–610 million annually. The company, which focuses on atrial fibrillation treatment and post-surgical pain management, has posted roughly 18% compound annual growth over five years, a 77% gross margin, and three consecutive quarters of net income. Pain management is driving expansion. Procedure volume grew about 25% in the latest quarter, aided by the cryoSPHERE MAX launch, which halves freeze time for certain procedures. Market penetration stands at around 20% in thoracic procedures, with room to grow in sternotomy and amputation applications. Clinical trials could expand AtriCure's market further. The BoxX-NoAF trial is expected to complete enrollment by year-end, with data due mid-2027. The larger LeAAPS trial may support broader AtriClip adoption if stroke-reduction results prove favourable.

Yahoo Finance
Jul 28th, 2026
AtriCure beats Q2 estimates with $153.6M revenue and 800% EPS surprise, raises full-year guidance

AtriCure reported second-quarter fiscal 2026 earnings on 23 July, with revenue of $153.6 million and adjusted EPS of $0.18, beating consensus estimates by $1.79 million and $0.16 respectively. The medical device company swung to a net profit of $9 million from a loss of $6.2 million in the same quarter last year. Gross margin improved to 77.2%, up 270 basis points year-on-year, driven by product innovation and efficiencies. US business grew 14% whilst worldwide revenue rose 13%. The pain management franchise saw 27% growth. AtriCure raised its full-year 2026 revenue guidance to $602 million-$610 million and adjusted EBITDA guidance to $85 million-$89 million. The company is enrolling patients in clinical trials targeting the post-operative atrial fibrillation market, valued at over $2 billion annually.

Yahoo Finance
Jul 24th, 2026
AtriCure reports $154M revenue, 13% growth and $9M net income in Q2 2026

AtriCure Inc reported strong second-quarter results with worldwide revenue of $154 million, representing 13% year-over-year growth. US revenue reached $125.6 million, up 13.6%, whilst international revenue grew 9.6% to $28 million. The medical device company achieved significant profitability improvements, posting net income of $9 million compared to a net loss of $6.2 million in the prior year. Adjusted EBITDA exceeded $27 million, with gross margin expanding to 77.2%. Pain management revenue led growth at 27.8% to $27.1 million, driven by adoption of cryoSPHERE MAX. Appendage management revenue increased 14.4% to $51.6 million, whilst open ablation revenue rose 12.1% to $40.9 million. The company raised full-year revenue guidance to $602-610 million, reflecting 12.5-14% growth over 2025. Adjusted EBITDA guidance was increased to $85-89 million. AtriCure also reported its BoxX-NoAF clinical study surpassed 50% enrollment ahead of schedule.

Yahoo Finance
Jun 4th, 2026
AtriCure accelerates heart disease trial by 12 months, beats Q1 revenue by $2M

AtriCure, a medical device company focused on atrial fibrillation treatments, reported first-quarter 2026 revenue of $141.2 million, up 14.3% year over year and exceeding analyst estimates by 1.4%. Growth was driven by a 28% increase in the pain management segment, led by its cryoSPHERE MAX probe. The company announced it has accelerated its BoxX-NoAF clinical trial timeline by 12 months, with patient enrollment now expected to complete by year-end and results potentially available in 2027 instead of 2028. The trial tests a minimally invasive procedure for treating atrial fibrillation. Following the results, Needham reiterated its Buy rating with a $45 price target on 6 May, citing the accelerated trial timeline as a major development that could unlock significant new market opportunities.